bioMerieux and GlaxoSmithKline sign agreement to develop test for breast cancer

Posted on: Wed, 18 Nov 2009 13:38:00 EST


Symbols: GSK
Nov 18, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
GSK | Quote | Chart | News | PowerRating -- bioMerieux SA, a France-based developer and manufacturer of biologic diagnostic products, has signed an agreement with GlaxoSmithKline plc (GSK), a UK-based pharmaceutical and healthcare company, to develop a predictive test. This test, based on biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings.

The development of this new test will be co-funded by both companies. GSKwill bring its experience in the field of cancer and will also facilitate access to samples from several clinical trials under the collaboration. The new test will be developed by bioMerieux's global research and development (R&D) team, including its subsidiary, bioTheranostics.

Deal Type    Partnership
Sub-Category Development
Deal Status Announced: 2009-11-17

Deal Participants

Partner 1 (Company) GlaxoSmithKline plc
Partner 2 (Company) bioMerieux SA
Partner 3 (Company) bioTheranostics

Deal Rationale

The development of this new test will be co-funded by both companies.

For full details on GlaxoSmithKline (GSK) GSK. GlaxoSmithKline (GSK) has Short Term PowerRatings at TradingMarkets. Details on GlaxoSmithKline (GSK) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.